University of Maryland, Baltimore
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Maryland, Baltimore sits in the top decile of US sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count).
University of Maryland, Baltimore: 560 sponsored US clinical trials, 103 recruiting.
University of Maryland, Baltimore sponsors 560 registered US clinical trials on ClinicalTrials.gov, 103 of them currently recruiting, and 332 completed. 77 of these trials are in Phase 3-4 (later-stage) and 161 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 14 trials.
Top-decile sponsor footprint
University of Maryland, Baltimore ranks in the top decile of sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
332 of 410 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
560 total, page 6 of 12
Function Focused Care: Fracture Care at Home
NCT03147222
Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis
NCT03396822
Use of a Rapid Test for Gonorrhea & Chlamydia for Women Presenting With Possible Sexually Transmitted Infections
NCT03098394
Relieving Acute Pain (RAP) Study: A Pilot Study
NCT03426137
Pre-operative Alcohol Skin Solutions in Fractured Extremities
NCT03523962
PUSH Plus Protein Pilot for Hip Fracture Patients
NCT03410823
Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During/After Heart Transplantation
NCT03341156
Hypothyroidism Treated With Calcitonin
NCT03342001
Biologic Mechanisms for Pain Variation After Physical Activity in Osteoarthritis
NCT03344913
Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures
NCT03385304
Examining a Training Program for for Acute Lymphoblastic Leukemia Childhood Cancer Survivors
NCT05086354
Acupuncture in Spinal Cord Injury Subjects
NCT03197675
Ceftaroline Pharmacokinetics in Continuous Renal Replacement Therapy
NCT04152694
Indocyanine Green Tissue Perfusion Monitoring
NCT02978560
Tailored Mindfulness Intervention in Adolescence
NCT03404349
Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection
NCT03312023
Cardiac MRI Biomarker Testing (GCC 1618)
NCT02688166
Functional Chewing Gum in Reduction of Gingival Inflammation
NCT03237624
Temporary Anchorage Devices for Ridge Preservation
NCT03205800
Effect of Heat on Oxybutynin Release and Absorption From Oxybutynin Products
NCT03205605
Preventing the Spread of Infection in Nursing Homes
NCT03319368
RCT of a Polyherbal Dietary Supplement for Prediabetes
NCT03388762
Harnessing Placebo Effects in Methadone Treatment
NCT02941809
Pharmacokinetics of Antiepileptics in Patients on CRRT
NCT03632915
Lung SBRT Motion Management (GCC 1619)
NCT02695680
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
NCT03133221
Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease
NCT03141905
TMS Enhancement of Visual Plasticity in Schizophrenia
NCT03220438
IV Iron Safety: Evaluation of Iron Species in Healthy Subjects
NCT02399449
MR Guided Focused Ultrasound for Treatment of Neuropathic Pain
NCT03111277
Dissemination and Implementation of Function Focused Care for Assisted Living
NCT03459118
CES1 Crossover Trial of Clopidogrel and Ticagrelor
NCT03161678
Confirmatory Efficacy Trial of a Gluten-Free Diet in a Subgroup of Persons With Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies (AGA IG)
NCT03183609
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD
NCT02884908
Prophylactic Topical Epinephrine to Reduce Bleeding in Transbronchial Lung Biopsies
NCT03126968
HIFLO ENDO-High Flow Nasal Cannula in GI Endoscopy
NCT03028688
Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma
NCT03116529
Ketogenic Diet and Prostate Cancer Surveillance Pilot
NCT03194516
Helping Veterans With SMI "StayQuit" From Smoking After Inpatient Hospitalization
NCT03367520
Maraviroc Efficacy for Hepatitis C
NCT02881762
Bronchial Mapping (GCC 1635)
NCT02745548
Incredible Years Program for Parents of Children with Autism
NCT03300128
Wellness Champions for Change
NCT03432715
Intraoral Imaging at Clinical Crown Lengthening
NCT03064217
HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant
NCT02902120
Evaluation of Bioavailability of Diclofenac Dermal Products
NCT03145259
Group and Mobile Care for Gestational Diabetes
NCT03026218
Minocycline and Tobacco Craving in Smokers With Schizophrenia
NCT02968602
Prostate Cancer Survey
NCT03128710
Effectiveness of an Alcohol-based Hand Rub to "Clean" Gloved Hands
NCT03445676
What is open in the University of Maryland, Baltimore pipeline
103 recruiting of 560 indexed (18% open); 332 completed (59%).
Phase mix: 77 late (III/IV) vs 161 early (I/II) (early-phase heavy).
Top condition: Schizophrenia (14 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Maryland, Baltimore: open-pipeline peers nationwide
Peers matched on 560 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
University of Maryland, Baltimore sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 560 trials (± recruiting share)
- Amgen · 558 trials · 10% recruiting
- Merck Sharp & Dohme · 558 trials · 22% recruiting
- Virginia Commonwealth University · 558 trials · 14% recruiting
- National Institute of Neurological Disorders and Stroke (NINDS) · 567 trials · 8% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Abramson Cancer Center at Penn Medicine · 18% recruiting · 402 trials
- Henry Ford Health System · 18% recruiting · 234 trials
- New York Institute of Technology · 18% recruiting · 49 trials
- University of California, San Diego · 18% recruiting · 775 trials
Related
What to do with this University of Maryland, Baltimore page
560 registered trials is a research-attention snapshot, not an endorsement of University of Maryland, Baltimore or any single study.
- 103 of University of Maryland, Baltimore's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Schizophrenia is the condition University of Maryland, Baltimore studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Maryland, Baltimore pipeline card: 560 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.